Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer : Appraisal consultation committee papers 1
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.